Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Amanda M. Smith 1, 2, 3, * , Matthew D. Dun 1, 2, * , Erwin M. Lee 4 , Celeste Harrison 1, 2 , Richard Kahl 1, 2 , Hayley Flanagan 1, 2 , Nikita Panicker 1, 2 , Baratali Mashkani 1, 2, 5 , Anthony S. Don 6 , Jonathan Morris 7 , Hamish Toop 7 , Richard B. Lock 4 , Jason A. Powell 8 , Daniel Thomas 8, 9 , Mark A. Guthridge 10 , Andrew Moore 11 , Leonie K. Ashman 1, 2 , Kathryn A. Skelding 1, 2 , Anoop Enjeti 1, 2, 12 , Nicole M. Verrills 1, 2 1 School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia 2 Hunter Medical Research Institute, Newcastle, New South Wales, Australia 3 Current address: The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia 4 Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, New South Wales, Australia 5 Current address: Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 6 Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia 7 School of Chemistry, University of New South Wales, Sydney, New South Wales, Australia 8 Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia 9 Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA 10 Department Clinical Haematology, Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia 11 Translational Research Institute, The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia 12 Calvary Mater Hospital, Newcastle, New South Wales, Australia * These authors contributed equally to this work Correspondence to: Nicole M. Verrills, email: nikki.verrills@newcastle.edu.au Keywords: PP2A, FTY720, AML, FLT3, tyrosine kinase inhibitor Received: April 07, 2016 Accepted: June 06, 2016 Published: June 18, 2016 ABSTRACT Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A). Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S). FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells. Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD + BaF3 and MV4-11 cell lines. PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts. Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits. AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes. Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD + cells. A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment. Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sphingosine-1-phosphate signaling and its role in disease
Maceyka, M., Harikumar, K. B., Milstien, S., & Spiegel, S. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.003 · Cited by 1,039 · cited 1×
“FTY720-P acts as a functional antagonist of the sphingosine-1-phosphate receptor mediated signaling pathway [30, 31].”
BackgroundProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400 · cited 2×
“FTY720 has been proposed as an anti-cancer agent [18, 40], however its efficacy may be limited with clinical toxicities including transient bradycardia, macular oedema, and brain inflammation, thought to be due to the effects of FTY720-P on sphingosine-1-phosphate receptors [41, 42].”
BackgroundMultiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344
Arnold, H. K., & Sears, R. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2832-2844.2006 · Cited by 251 · cited 1×
“For example, loss of PP2A-B56α results in accumulation of c-MYC [55], while reduced PP2A-B55α leads to enhanced phosphorylation of AKT [56, 57], both important downstream effectors of FLT3.”
BackgroundSents, W., Ivanova, E., Lambrecht, C., Haesen, D., & Janssens, V. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08579.x · Cited by 204 · cited 1×
“PP2A is a multimeric family of enzymes each composed of a catalytic (C), a scaffold (A), and one of a number of regulatory subunits (B/B55/PR55, B’/B56/PR56/PR61, B’’/PR48/PR72/130, B’’’/PR93/PR110) that direct subcellular localization and substrate specificity (for a comprehensive review of PP2A structure and functio…”
BackgroundStructure, Regulation, and Pharmacological Modulation of PP2A Phosphatases
Lambrecht, C., Haesen, D., Sents, W., Ivanova, E., & Janssens, V. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-562-0_17 · Cited by 140
Ruediger, R., Ruiz, J., & Walter, G. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05744-11 · Cited by 98 · cited 1×
“PP2A-A knockdown has been shown to induce a concomitant loss of PP2A-B55, -B56α and –B56δ subunit proteins, and reduced PP2A activity [48, 49], therefore, the decreased PP2A-A may also contribute to the downregulation of PP2A-B subunits we observed in the FLT3-ITD cells.”
Background
Cited by
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“A nice example of the effectiveness of such a strategy in a pre-clinical setting is the benefit of combining PP2A activators (PADs) and tyrosine kinase inhibitors (TKIs) in hematologic malignancies characterized by nongenetically inhibited PP2A (628, 658-661).”
BackgroundPP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.009 · Cited by 93
Functional importance of PP2A regulatory subunit loss in breast cancer
Watt, L. F., Panicker, N., Mannan, A., Copeland, B., Kahl, R. G. S., Dun, M. D., Young, B., Roselli, S., & Verrills, N. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4403-5 · Cited by 29
Self-citation
Metadata
- Authors
- Smith, A. M., Dun, M. D., Lee, E. M., Harrison, C., Kahl, R., Flanagan, H., Panicker, N., Mashkani, B., Don, A. S., Morris, J., Toop, H., Lock, R. B., Powell, J. A., Thomas, D., Guthridge, M. A., Moore, A., Ashman, L. K., Skelding, K. A., Enjeti, A., & Verrills, N. M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-06-18
- Volume
- 7
- Issue
- 30
- Pages
- 47465-47478
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2430824944
- Cited by
- 51
- References
- 7
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.